公开(公告)号：US11234977B2

公开(公告)日：2022-02-01

申请号：US16956527

申请日：2018-12-19

Applicant: Novartis AG

Inventor： Jiping Fu ,  Wooseok Han ,  Xianming Jin ,  Keith Bruce Pfister ,  Joseph Michael Young

IPC: C07D471/14 ,  A61K31/4985 ,  A01N43/90 ,  A61P31/20 ,  A61K47/60 ,  A61K38/21 ,  A61K45/06

Abstract: The invention provides compounds of Formula (I) as described herein, along with pharmaceutically acceptable salts, pharmaceutical compositions and pharmaceutical combinations containing such compounds, as well as methods to use these compounds, salts and compositions for treating viral infections, particularly infections caused by hepatitis B virus (HBV), and for reducing the occurrence of serious conditions associated with HBV.

公开(公告)号：US10093673B2

公开(公告)日：2018-10-09

申请号：US15782722

申请日：2017-10-12

Applicant: Novartis AG

Inventor： Jiping Fu ,  Xianming Jin ,  Patrick Lee ,  Peichao Lu ,  Joseph Michael Young

IPC: C07D491/147 ,  C07D471/14 ,  A61K31/4375 ,  C07D217/08 ,  C07D491/14

Abstract: The invention provides compounds of Formula (I) as described herein, along with pharmaceutically acceptable salts, pharmaceutical compositions containing such compounds, and methods to use these compounds, salts and compositions for treating viral infections, particularly infections caused by hepatitis B virus, and reducing the occurrence of serious conditions associated with HBV.

公开(公告)号：US09845325B2

公开(公告)日：2017-12-19

申请号：US15435137

申请日：2017-02-16

Applicant: Novartis AG

Inventor： Jiping Fu ,  Xianming Jin ,  Patrick Lee ,  Peichao Lu ,  Joseph Michael Young

IPC: C07D491/147 ,  C07D471/14 ,  A61K31/4375

CPC classification number: C07D471/14 ,  A61K31/4375 ,  C07D217/08 ,  C07D491/14 ,  C07D491/147

Abstract: The invention provides compounds of Formula (I) as described herein, along with pharmaceutically acceptable salts, pharmaceutical compositions containing such compounds, and methods to use these compounds, salts and compositions for treating viral infections, particularly infections caused by hepatitis B virus, and reducing the occurrence of serious conditions associated with HBV.

公开(公告)号：US09815804B2

公开(公告)日：2017-11-14

申请号：US15375560

申请日：2016-12-12

Applicant: Novartis AG

Inventor： Jiping Fu ,  Xianming Jin ,  Subramanian Karur ,  Guillaume Lapointe ,  Ann Marie Madera ,  Zachary Kevin Sweeney

IPC: C07D261/08 ,  A61K31/42 ,  A61K45/06 ,  C07D413/12 ,  A61K31/422 ,  C07D413/06

CPC classification number: C07D261/08 ,  A61K31/42 ,  A61K31/422 ,  A61K45/06 ,  C07D413/06 ,  C07D413/12 ,  Y02A50/473 ,  Y02A50/475 ,  Y02A50/478 ,  Y02A50/481 ,  A61K2300/00

Abstract: This invention pertains generally to compounds of Formula I as described herein and compositions containing such compounds, as well as methods of using such compounds to treat bacterial infections. In certain aspects, the invention provides methods and compositions comprising these compounds for treating infections caused by Gram-negative bacteria.

公开(公告)号：US10975078B2

公开(公告)日：2021-04-13

申请号：US16808985

申请日：2020-03-04

Applicant: Novartis AG

Inventor： Jiping Fu ,  Wooseok Han ,  Subramanian Karur ,  Peichao Lu ,  Keith Bruce Pfister ,  Joseph Michael Young

IPC: C07D471/14 ,  C07D405/12 ,  A61P31/12 ,  C07D491/16 ,  C07D401/12 ,  A61K45/06 ,  A61K31/4985 ,  C07D471/22

Abstract: The invention provides compounds of Formula (I) as described herein, along with pharmaceutically acceptable salts, pharmaceutical compositions containing such compounds, and methods to use these compounds, salts and compositions for treating viral infections, particularly infections caused by hepatitis B virus, and reducing the occurrence of serious conditions associated with HBV.

公开(公告)号：US10029994B2

公开(公告)日：2018-07-24

申请号：US15728351

申请日：2017-10-09

Applicant: Novartis AG

Inventor： Jiping Fu ,  Xianming Jin ,  Subramanian Karur ,  Guillaume Lapointe ,  Ann Marie Madera ,  Zachary Kevin Sweeney

IPC: C07D261/08 ,  C07D413/12 ,  C07D413/06 ,  A61K31/422 ,  A61K45/06 ,  A61K31/42

Abstract: This invention pertains generally to compounds of Formula I as described herein and compositions containing such compounds, as well as methods of using such compounds to treat bacterial infections. In certain aspects, the invention provides methods and compositions comprising these compounds for treating infections caused by Gram-negative bacteria.

公开(公告)号：US09718792B2

公开(公告)日：2017-08-01

申请号：US15454187

申请日：2017-03-09

Applicant: Novartis AG

Inventor： Jiping Fu ,  Xianming Jin ,  Subramanian Karur ,  Guillaume LaPointe ,  Patrick Lee ,  Zachary Kevin Sweeney

IPC: C07D417/10 ,  C07D261/04 ,  A61K31/42 ,  C07D413/04 ,  A61K31/4439 ,  C07D413/10 ,  A61K31/5377 ,  A61K31/427 ,  A61K31/422 ,  A61K45/06

CPC classification number: C07D261/04 ,  A61K31/42 ,  A61K31/421 ,  A61K31/422 ,  A61K31/427 ,  A61K31/4439 ,  A61K31/5377 ,  A61K45/06 ,  C07D413/04 ,  C07D413/10 ,  C07D417/10

Abstract: This invention pertains generally to compounds of Formula I and compositions containing such compounds, as well as methods of using such compounds to treat bacterial infections. In certain aspects, the invention pertains to methods and compositions for treating infections caused by Gram-negative bacteria.

公开(公告)号：US20130149281A1

公开(公告)日：2013-06-13

申请号：US13764509

申请日：2013-02-11

Applicant: NOVARTIS AG

Inventor： Trixi Brandl ,  Jiping Fu ,  Francois Lenoir ,  David Thomas Parker ,  Michael Patane ,  Branko Radetich ,  Prakash Raman ,  Pascal Rigollier ,  Mohindra Seepersaud ,  Oliver Simic ,  Aregahegn Yifru ,  Rui Zhang

IPC: A61K38/07 ,  A61K45/06 ,  A61K38/06

CPC classification number: A61K38/07 ,  A61K38/00 ,  A61K38/06 ,  A61K45/06 ,  C07D209/96 ,  C07D401/12 ,  C07D401/14 ,  C07D403/12 ,  C07D405/12 ,  C07D409/12 ,  C07D413/12 ,  C07D413/14 ,  C07D417/12 ,  C07D417/14 ,  C07D487/10 ,  C07D491/20 ,  C07D495/10 ,  C07D498/04 ,  C07D498/10 ,  C07K5/06034 ,  C07K5/06078 ,  C07K5/06165 ,  C07K5/0808 ,  C07K5/0812 ,  C07K5/101 ,  C07K5/1016

Abstract: The present application describes a method of treating an HCV-associated disorder by administering to a subject in need thereof a pharmaceutically effective amount of a compound of formula I in combination with an additional HCV-modulating compound.

Abstract translation: 本申请描述了通过向有需要的受试者施用药学有效量的式I化合物与另外的HCV调节化合物组合来治疗HCV相关疾病的方法。

公开(公告)号：US20220105091A1

公开(公告)日：2022-04-07

申请号：US17551080

申请日：2021-12-14

Applicant: Novartis AG

Inventor： Jiping Fu ,  Wooseok Han ,  Xianming Jin ,  Keith Bruce Pfister ,  Joseph Michael Young

IPC: A61K31/4985 ,  A61K47/60 ,  A61P31/20 ,  A01N43/90 ,  A61K38/21 ,  A61K45/06 ,  C07D471/14

Abstract: The invention provides compounds of Formula (I) as described herein, along with pharmaceutically acceptable salts, pharmaceutical compositions and pharmaceutical combinations containing such compounds, as well as methods to use these compounds, salts and compositions for treating viral infections, particularly infections caused by hepatitis B virus (HBV), and for reducing the occurrence of serious conditions associated with HBV.

公开(公告)号：US10301312B2

公开(公告)日：2019-05-28

申请号：US15965172

申请日：2018-04-27

Applicant: Novartis AG

Inventor： Jiping Fu ,  Wooseok Han ,  Subramanian Karur ,  Peichao Lu ,  Keith Bruce Pfister ,  Joseph Michael Young

IPC: C07D471/14 ,  C07D405/12 ,  A61P31/12 ,  C07D491/16 ,  C07D401/12 ,  A61K45/06 ,  A61K31/4985 ,  C07D471/22

Abstract: The invention provides compounds of Formula (I) as described herein, along with pharmaceutically acceptable salts, pharmaceutical compositions containing such compounds, and methods to use these compounds, salts and compositions for treating viral infections, particularly infections caused by hepatitis B virus, and reducing the occurrence of serious conditions associated with HBV.